APOE-3 and TOMM-40 Haplotypes Determine Inheritance of Alzheimer's Disease Independently of APOE-4 Risk

Article

Noting that estimates for the heritability of apolipoprotein E-4 (APOE-4) for late-onset Alzheimer’s disease (ranging from 58-79%) and the population-attributable risk due to the APOE-4 allele (ranging from 20-70%) suggest that “other genetic variants or interactions between variants incur additional risk and modify age of onset distributions.” Also taking into account the “extraordinary association” for AD with the linkage disequilibrium (LD) region containing APOE, and that TOMM-40, the “protein translocase of the outer mitochondrial membrane,” is also in high LD with APOE, Allen D. Roses, of Duke University and the Deane Drug Discovery Institute, and colleagues sought to identify new haplotypes with this LD region that may increase estimates of heritability. They studies the TOMM-40/APOE-4 LD region in 66 patients with AD and 66 age-matched controls. They found that “unique and distinct inherited families of different TOMM-40 variants are located on the same genetic interval as APOE-3,” but not on the APOE-4 genetic region. These variants can “either increase or decrease the age of risk distribution of AD.” They concluded that “the genetic inheritance of these TOMM-40 variants is independent of the inheritance of APOE-4, providing a differentiation of two distinct forms of APOE-3: those linked to TOMM-40 haplotypes that increase risk and decrease age of onset, and those that decrease risk.”

Related Videos
Daniel Karlin, MD: Prevalence of Undiagnosed Generalized Anxiety Disorder
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
The Future of DSM-5-TR with APA Members Nitin Gogtay, Maria Oquendo, Jonathan Alpert
Ashkan Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy | Image Credit: Texas Retina AssociatesImage Credit:
Paul Appelbaum, MD: What to Warn Patients When Prescribing Psychedelics in the Future
Clozapine and Second-Generation Antipsychotics for Schizophrenia, with John Kane, MD
Ryan McLaughlin, PhD: Challenges Studying Cannabis to Treat Psychiatric Illness
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Charles R. Marmar, MD: Blood Biomarkers for PTSD
© 2024 MJH Life Sciences

All rights reserved.